Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Keratitis | 10 | 2026 | 105 | 3.570 |
Why?
|
| Eye Infections, Fungal | 7 | 2026 | 68 | 3.350 |
Why?
|
| Diaphragm | 4 | 2025 | 102 | 3.050 |
Why?
|
| Rose Bengal | 13 | 2026 | 16 | 3.040 |
Why?
|
| Photochemotherapy | 12 | 2026 | 40 | 2.930 |
Why?
|
| Photosensitizing Agents | 10 | 2026 | 36 | 2.680 |
Why?
|
| Respiration, Artificial | 4 | 2025 | 501 | 2.200 |
Why?
|
| Electromyography | 2 | 2025 | 141 | 1.770 |
Why?
|
| Cornea | 5 | 2026 | 566 | 1.730 |
Why?
|
| Airway Extubation | 2 | 2025 | 70 | 1.510 |
Why?
|
| Corneal Ulcer | 4 | 2023 | 53 | 1.460 |
Why?
|
| Ventilator Weaning | 3 | 2025 | 30 | 1.340 |
Why?
|
| Anti-Infective Agents | 6 | 2024 | 265 | 1.320 |
Why?
|
| Riboflavin | 6 | 2026 | 31 | 1.300 |
Why?
|
| Antifungal Agents | 4 | 2026 | 298 | 1.270 |
Why?
|
| Fusarium | 4 | 2026 | 15 | 1.220 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2025 | 124 | 1.090 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2026 | 234 | 0.910 |
Why?
|
| Byssochlamys | 1 | 2024 | 1 | 0.850 |
Why?
|
| Scedosporium | 1 | 2024 | 7 | 0.850 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2023 | 18 | 0.790 |
Why?
|
| Staphylococcal Infections | 2 | 2026 | 569 | 0.770 |
Why?
|
| Electrocardiography | 2 | 2025 | 983 | 0.760 |
Why?
|
| Visual Acuity | 1 | 2025 | 537 | 0.740 |
Why?
|
| Mycoses | 1 | 2023 | 110 | 0.740 |
Why?
|
| Corneal Diseases | 1 | 2023 | 94 | 0.730 |
Why?
|
| Collagen | 3 | 2023 | 289 | 0.710 |
Why?
|
| Cytokines | 1 | 2026 | 1347 | 0.630 |
Why?
|
| Silicone Elastomers | 1 | 2019 | 23 | 0.600 |
Why?
|
| Cataract | 1 | 2019 | 152 | 0.560 |
Why?
|
| Phacoemulsification | 1 | 2019 | 132 | 0.530 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2019 | 186 | 0.530 |
Why?
|
| Fusariosis | 3 | 2026 | 5 | 0.520 |
Why?
|
| Lenses, Intraocular | 1 | 2019 | 215 | 0.520 |
Why?
|
| Ophthalmology | 1 | 2019 | 178 | 0.510 |
Why?
|
| Quality of Life | 1 | 2025 | 2107 | 0.460 |
Why?
|
| Iontophoresis | 1 | 2014 | 6 | 0.430 |
Why?
|
| Keratoconus | 1 | 2014 | 47 | 0.410 |
Why?
|
| Fungi | 1 | 2014 | 73 | 0.410 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2025 | 174 | 0.340 |
Why?
|
| Pilot Projects | 5 | 2026 | 1450 | 0.340 |
Why?
|
| Microscopy, Confocal | 3 | 2024 | 363 | 0.330 |
Why?
|
| Humans | 23 | 2026 | 131504 | 0.310 |
Why?
|
| Natamycin | 2 | 2026 | 5 | 0.300 |
Why?
|
| Amphotericin B | 2 | 2026 | 90 | 0.290 |
Why?
|
| Cross-Linking Reagents | 2 | 2021 | 50 | 0.280 |
Why?
|
| Aspergillus | 1 | 2026 | 26 | 0.240 |
Why?
|
| Entropy | 1 | 2025 | 28 | 0.230 |
Why?
|
| Scleritis | 1 | 2025 | 10 | 0.230 |
Why?
|
| Aged | 6 | 2025 | 21238 | 0.220 |
Why?
|
| Middle Aged | 8 | 2025 | 28839 | 0.220 |
Why?
|
| Epithelium, Corneal | 1 | 2026 | 174 | 0.210 |
Why?
|
| Pseudomonas Infections | 1 | 2025 | 117 | 0.210 |
Why?
|
| Salivary Glands, Minor | 1 | 2023 | 9 | 0.200 |
Why?
|
| Ulcer | 1 | 2023 | 51 | 0.200 |
Why?
|
| Mucous Membrane | 1 | 2023 | 88 | 0.190 |
Why?
|
| Respiratory Rate | 1 | 2022 | 7 | 0.190 |
Why?
|
| Steroids | 1 | 2023 | 172 | 0.190 |
Why?
|
| Nocardia | 1 | 2022 | 8 | 0.180 |
Why?
|
| Rabbits | 2 | 2021 | 633 | 0.180 |
Why?
|
| Respiratory System | 1 | 2022 | 97 | 0.180 |
Why?
|
| Fluorescent Dyes | 2 | 2021 | 251 | 0.180 |
Why?
|
| Prostheses and Implants | 1 | 2023 | 143 | 0.180 |
Why?
|
| Machine Learning | 1 | 2025 | 375 | 0.180 |
Why?
|
| Prosthesis Implantation | 1 | 2023 | 145 | 0.180 |
Why?
|
| Thorax | 1 | 2021 | 71 | 0.170 |
Why?
|
| Male | 8 | 2025 | 65158 | 0.170 |
Why?
|
| Vision Disorders | 1 | 2023 | 197 | 0.170 |
Why?
|
| Eye Infections, Bacterial | 1 | 2021 | 79 | 0.170 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2026 | 846 | 0.160 |
Why?
|
| Eye Infections | 1 | 2019 | 3 | 0.160 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2019 | 36 | 0.150 |
Why?
|
| Visual Field Tests | 1 | 2019 | 50 | 0.150 |
Why?
|
| Smartphone | 1 | 2019 | 46 | 0.150 |
Why?
|
| Female | 10 | 2025 | 71087 | 0.150 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2019 | 17 | 0.150 |
Why?
|
| Spironolactone | 1 | 2019 | 22 | 0.150 |
Why?
|
| Intraocular Pressure | 1 | 2019 | 133 | 0.150 |
Why?
|
| Choroidal Neovascularization | 1 | 2019 | 21 | 0.140 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2019 | 45 | 0.140 |
Why?
|
| Bioreactors | 1 | 2018 | 44 | 0.140 |
Why?
|
| Algorithms | 1 | 2025 | 1685 | 0.140 |
Why?
|
| Clinical Trials as Topic | 1 | 2023 | 1139 | 0.140 |
Why?
|
| Visual Fields | 1 | 2019 | 141 | 0.140 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 4684 | 0.140 |
Why?
|
| Postoperative Period | 1 | 2019 | 330 | 0.140 |
Why?
|
| Light | 2 | 2019 | 174 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2019 | 110 | 0.140 |
Why?
|
| Macular Degeneration | 1 | 2019 | 91 | 0.130 |
Why?
|
| Prosthesis Design | 1 | 2019 | 610 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 5277 | 0.120 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 4037 | 0.110 |
Why?
|
| Rats, Inbred Lew | 1 | 2014 | 67 | 0.110 |
Why?
|
| Aspergillus fumigatus | 1 | 2014 | 43 | 0.110 |
Why?
|
| Bacteriological Techniques | 1 | 2014 | 86 | 0.100 |
Why?
|
| Candida albicans | 1 | 2014 | 88 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 211 | 0.100 |
Why?
|
| Animals | 6 | 2022 | 34341 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 2 | 2025 | 2566 | 0.090 |
Why?
|
| Adult | 3 | 2025 | 31666 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2019 | 12936 | 0.070 |
Why?
|
| Rats | 1 | 2014 | 3454 | 0.070 |
Why?
|
| Ultraviolet Rays | 2 | 2019 | 195 | 0.070 |
Why?
|
| Voriconazole | 1 | 2026 | 30 | 0.060 |
Why?
|
| Gels | 1 | 2023 | 70 | 0.050 |
Why?
|
| Florida | 1 | 2022 | 72 | 0.050 |
Why?
|
| Sheep | 1 | 2022 | 224 | 0.040 |
Why?
|
| Regeneration | 1 | 2023 | 230 | 0.040 |
Why?
|
| Keratoplasty, Penetrating | 1 | 2019 | 48 | 0.040 |
Why?
|
| Ophthalmic Solutions | 1 | 2019 | 88 | 0.040 |
Why?
|
| Euryarchaeota | 1 | 2018 | 2 | 0.040 |
Why?
|
| Biological Oxygen Demand Analysis | 1 | 2018 | 4 | 0.040 |
Why?
|
| Anaerobiosis | 1 | 2018 | 14 | 0.040 |
Why?
|
| Bacteria, Anaerobic | 1 | 2018 | 8 | 0.040 |
Why?
|
| Ranibizumab | 1 | 2019 | 12 | 0.040 |
Why?
|
| Manure | 1 | 2018 | 6 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2019 | 41 | 0.040 |
Why?
|
| Chemical Phenomena | 1 | 2018 | 81 | 0.040 |
Why?
|
| Methane | 1 | 2018 | 18 | 0.040 |
Why?
|
| Choroid | 1 | 2019 | 23 | 0.040 |
Why?
|
| Microspheres | 1 | 2019 | 68 | 0.040 |
Why?
|
| Intravitreal Injections | 1 | 2019 | 40 | 0.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2019 | 54 | 0.040 |
Why?
|
| Rats, Long-Evans | 1 | 2019 | 98 | 0.040 |
Why?
|
| Fatty Acids, Volatile | 1 | 2018 | 44 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 6916 | 0.030 |
Why?
|
| Equipment Design | 1 | 2019 | 553 | 0.030 |
Why?
|
| Cattle | 1 | 2018 | 521 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2019 | 341 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2021 | 463 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2019 | 692 | 0.030 |
Why?
|
| Gene Expression | 1 | 2019 | 1500 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2025 | 17648 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 2363 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2019 | 6485 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 10092 | 0.010 |
Why?
|
| Mice | 1 | 2019 | 18473 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 20917 | 0.010 |
Why?
|